REAL LIFE TREATMENT DURATION OF SORAFENIB OR SUNITINIB IN FIRST LINE METASTATIC RENAL CELL CARCINOMA PATIENTS-A COMPARATIVE ANALYSIS

被引：0
|
作者：
Hammerman, A. [1 ]
Klang, S. H. [1 ]
Liebermann, N. [1 ]
机构：
[1] Clalit Hlth Serv, Tel Aviv, Israel
来源：
VALUE IN HEALTH | 2009年 / 12卷 / 07期
关键词：
D O I：
10.1016/S1098-3015(10)74272-8
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A260 / A260
页数：1
相关论文
共 50 条
  • [21] Sorafenib versus sunitinib as first-line treatment agents in Chinese patients with metastatic renal cell carcinoma: the largest multicenter retrospective analysis of survival and prognostic factors
    Zhang, Hai-Liang
    Sheng, Xi-Nan
    Li, Xue-Song
    Wang, Hong-Kai
    Chi, Zhi-Hong
    He, Zhi-Song
    Ye, Ding-Wei
    Guo, Jun
    BMC CANCER, 2017, 17
  • [22] SAFETY PROFILE OF SUNITINIB AND SORAFENIB IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA (MRCC)
    Massari, Francesco
    Sperandi, Francesca
    Cricca, Antonia
    Melotti, Barbara
    Martoni, Andrea Angelo
    ANNALS OF ONCOLOGY, 2009, 20
  • [23] Sorafenib versus sunitinib as first-line treatment agents in Chinese patients with metastatic renal cell carcinoma: the largest multicenter retrospective analysis of survival and prognostic factors
    Hai-Liang Zhang
    Xi-Nan Sheng
    Xue-Song Li
    Hong-Kai Wang
    Zhi-Hong Chi
    Zhi-Song He
    Ding-Wei Ye
    Jun Guo
    BMC Cancer, 17
  • [24] Sorafenib in Patients With Metastatic Renal Cell Carcinoma Refractory to Either Sunitinib or Bevacizumab
    Garcia, Jorge A.
    Hutson, Thomas E.
    Elson, Paul
    Cowey, C. Lance
    Gilligan, Timothy
    Nemec, Cheryl
    Dreicer, Robert
    Bukowski, Ronald M.
    Rini, Brian I.
    CANCER, 2010, 116 (23) : 5383 - 5390
  • [25] A Pooled Analysis of Sequential Therapies with Sorafenib and Sunitinib in Metastatic Renal Cell Carcinoma
    Stenner, Frank
    Chastonay, Rahel
    Liewen, Heike
    Haile, Sarah R.
    Cathomas, Richard
    Rothermundt, Christian
    Siciliano, Raffaele D.
    Stoll, Susanna
    Knuth, Alexander
    Buchler, Tomas
    Porta, Camillo
    Renner, Christoph
    Samaras, Panagiotis
    ONCOLOGY, 2012, 82 (06) : 333 - 340
  • [26] Metastatic Tumor Burden and Loci as Predictors of First Line Sunitinib Treatment Efficacy in Patients with Renal Cell Carcinoma
    Czarnecka, Anna M.
    Brodziak, Anna
    Sobczuk, Pawel
    Dendek, Cezary
    Labochka, Dominika
    Korniluk, Jan
    Bartnik, Ewa
    Szczylik, Cezary
    SCIENTIFIC REPORTS, 2019, 9 (1)
  • [27] EFFICACY AND SAFETY OF SUNITINIB AS FIRST-LINE TREATMENT IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA: SYSTEMATIC REVIEW
    Huerfano, C.
    NinoNino, C. P.
    Davila, F.
    Reyes, J. M.
    Diaz, J. A.
    VALUE IN HEALTH, 2016, 19 (03) : A169 - A169
  • [28] Metastatic Tumor Burden and Loci as Predictors of First Line Sunitinib Treatment Efficacy in Patients with Renal Cell Carcinoma
    Anna M. Czarnecka
    Anna Brodziak
    Pawel Sobczuk
    Cezary Dendek
    Dominika Labochka
    Jan Korniluk
    Ewa Bartnik
    Cezary Szczylik
    Scientific Reports, 9
  • [29] BUDGET IMPACT MODEL OF SUNITINIB AS FIRST LINE TREATMENT OF METASTATIC RENAL CELL CARCINOMA IN CHINA
    Wu, X.
    Shi, Q.
    Huang, Y.
    Yin, H.
    Li, M.
    Patel, S.
    Wu, Y.
    VALUE IN HEALTH, 2014, 17 (07) : A734 - A734
  • [30] Evaluation of the effectiveness and tolerability of sunitinib and pazopanib in the first line treatment of metastatic renal cell carcinoma
    Ebinc, Senar
    Kalkan, Ziya
    Oruc, Zeynep
    Urakci, Zuhat
    Kucukoner, Mehmet
    Kaplan, Muhammet Ali
    Isikdogan, Abdurrahman
    ONCOLOGY IN CLINICAL PRACTICE, 2022, 18 (04): : 226 - 234
12345